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Mechanism of impaired natriuretic response to furosemide during
prolonged therapy. The mechanism of the diuretic braking phenomenon
was studied in nine male hypertensive patients by assessing the diurnal
pattern of renal sodium (Na) excretion during furosemide therapy, and
the response to a test dose of furosemide (10 to 15 mg hr i.v.) infused
alone and with chlorothiazide (500 mg bolus i.v.). Patients were studied
after one month of twice-daily administration of: placebo (P); chlorothi-
azide 500mg (C); furosemide 40mg (F); furosemide with spironolactone
(100 mg b.i.d.) for the last 36 hours (F + S; N = 6). During F therapy,
furosemide-induced natnuresis was followed by six hour periods of
decreased UNaV. Diuretic therapy with F or C for one month reduced
BP, but did not alter body weight, plasma volume (PV), glomerular
filtration rate or PAH clearance. After P. the test infusion of furosemide
increased fractional Na excretion (FENa) by + 10.5 0.7%; this
increment was reduced after therapy with F (+8.9 0.7%; P < 0.05),
C (+8.5 1.0%; P < 0.01), or F + S (+8.9 0.9%; P < 0.05). Renal
furosemide excretion was greater (P < 0.05) after F and C treatments
(133 10 ig . min' and 130 13 p.g min, respectively) compared
with P (94 9 min '). After P, a test dose of chlorothiazide given
during furosemide infusion increased FENa further (+7.5 1.2%); this
increment was greater after therapy with F (+ 10.1 1.4%; P < 0.01)
and F + S (+11.3 0.8%; P < 0.05) but not after C (+6.3 1.5%; P
> 0.1). In conclusion, continuing Na losses during established furo-
semide therapy are prevented by reductions in UNaV following diuretic
action, and by a reduced natriuretic response to furosemide despite its
increased delivery to the tubule lumen. This reduced response was
without detectable changes in PV, or renal hemodynamics, and was
independent of the class of diuretic given. It was not prevented by an
aldosterone antagonist, but was related to increased Na reabsorption in
a thiazide-sensitive nephron segment, probably including the distal
convoluted tubule.
The first dose of a diuretic increases urine flow rate (UV) and
renal sodium excretion (UNaV), and decreases body weight.
However, with repeated administration, progressive losses of
Na and water are soon curtailed, and the reduced body weight
stabilizes. In previous studies we have examined this "diuretic
braking phenomenon" [1] in normal subjects taking furosemide
40 mg daily [2—5]. In subjects adapted to a high Na intake (280
mmol• 24 hr1), negative Na balance was prevented by a
period of post-diuretic salt retention, whereas in subjects
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adapted to a low Na intake (20 mmol . 24 hr ')it was prevented
by a reduced natriuretic response to the diuretic. There have
been no studies to determine which of these phenomena limit
further Na losses during prolonged diuretic therapy in man, or
their likely mechanisms.
Sodium-restricted rats given regular doses of loop, or thia-
zide, diuretics rapidly develop an impaired response to the drug
[6—8]. This is associated with a fall in plasma volume (PV) and
glomerular filtration rate (GFR), enhanced proximal tubule fluid
reabsorption and reduced filtrate delivery to the sites of diuretic
action (loop of Henle and distal convoluted tubule, respective-
ly). In contrast, comparable studies in patients with hyperten-
sion receiving thiazide diuretics have shown that initial falls in
PV, GFR and renal blood flow (RBF) return to baseline levels
after several weeks of continuing therapy [9, 10]. Thus, the
mechanism of diuretic braking may depend on the duration of
treatment, such as, initial hemodynamic and physical factors
versus later specific changes in tubule function.
Studies in rats have shown that six to eight days of continu-
ous furosemide infusion cause hypertrophy of the distal convo-
luted tubule [11—13], connecting tubule and principal cells of the
collecting ducts [12, 13]. This is accompanied by increased
Na/K ATPase of the collecting ducts [14, 15] and, in one study
[14] but not in another [15], of the distal convoluted tubule also.
Microperfusion studies have demonstrated an enhanced capac-
ity for Na reabsorption and K secretion by the distal tubule in
this adapted state [12, 16]. Therefore, the specific change in
tubule function that mediates diuretic braking could be en-
hanced Na and fluid reabsorption in adapted and hypertrophied
nephron segments beyond the site of diuretic action; this might
arise in response to the increased delivery of filtrate.
The aim of this study was to examine possible mechanisms
for the diuretic braking phenomenon in patients with mild-
to-moderate essential hypertension, treated with furosemide.
The response to a test intravenous (i.v.) infusion of furosemide
was studied in each subject after one month of placebo (P) and
compared with the response after one month of diuretic therapy
with furosemide (F), or chlorothiazide (C). We studied three
possible mechanisms: (I) the role of aldosterone was assessed
by giving its antagonist spironolactone; (2) intravenous chlo-
rothiazide was given during the test furosemide infusion to
block distal tubule Na reabsorption and thus estimate the
contribution of this nephron segment to any adaptive changes in
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reabsorption; (3) the rate of furosemide excretion was measured
to determine if altered delivery of furosemide to its luminal site
of action was a factor.
Methods
Subjects
Nine patients (aged 28 to 70 years; median 56 years) with
mild-to-moderate hypertension (diastolic BP 90 to 104 mm Hg
on 2 occasions while on no antihypertensive medication for I
month) took part in the study, which was approved by the
Institutional Review Board, University of Florida and the
Subcommittee for Human Investigation, Gainesville VAMC.
Each subject gave informed consent. Exclusion criteria were: a
history of myocardial infarction, renal disease or stroke; abnor-
mal values of blood urea nitrogen (BUN), serum creatinine
(Sr), electrolytes or hemoglobin.
Each subject was studied on three separate occasions after
one month of either placebo, furosemide 40 mg, or chlorothi-
azide 500 mg, given orally twice daily (b.i.d.). Five of the nine
subjects were also studied after one month of furosemide (40 mg
b.i.d.), with the addition of spironolactone (100 mg every 12 hr)
for the last 36 hours of oral furosemide (F + S); this was always
the last study protocol in these subjects. Drugs were taken at
08.00 and 20.00 hours, and the last dose (except S) was taken at
20.00 hours on the evening before study. All subjects were
asked not to add salt to their food.
Subjects were selected from patients routinely attending a
hypertension clinic. Their medication was withdrawn one
month before random allocation to each study protocol (P. F or
C), and they were followed as outpatients. At the end of each
month's treatment there was a study day during which re-
sponses to i.v. furosemide were measured. For the last 48 hours
of P and F treatment, subjects made six-hour urine collections
from 08.00 to 08.00 hours; two 24 hour urine collections were
obtained while on C and F + S treatment.
On the day of study, subjects were asked to eat a light
breakfast and report at 08.00 hours. This was 12 hours after
their last dose of placebo, furosemide or chlorothiazide. They
were weighed and their supine BP recorded. Forearm veins
were cannulated in both arms, one for sampling and the other
for bolus and continuous injection of m[Tc]diethylenetri
aminepentaacetic acid (DTPA; I Ci . kg' loading dose and
0,014 sCi . kg' . min maintenance) to estimate glomerular
filtration rate (GFR), and sodium paraaminohippurate (PAH;
8.6mg. kg' loading dose and 0.20mg. kg' min mainte-
nance)to estimate renal plasma flow (RPF) and Evans Blue (150
g. kg—'; blood sampling at +10, +20 and +30 mm) to
estimate plasma volume (PV) [17, 18]. Subjects remained su-
pine, but stood to pass urine. No smoking was allowed and a
light standardized lunch was eaten before the furosemide infu-
sion. An oral water load of 350 ml was given at the start and
again with lunch.
After one hour for equilibration, there was a basal clearance
period of(Ul) for measurement of GFR, RPF, PV, plasma renin
activity (PRA), hematocrit (Hct), BUN, Se,. and plasma and
urine electrolyte concentrations. Subjects were then given an
i.v. bolus injection of furosemide (10 mg) followed by a contin-
uous maintenance infusion (IS mg . hC'). Urine collections
were made every 30 minutes. Blood was taken after two hours
of furosemide for PRA, and Hct. After 150 minutes of furo-
semide, during which urine was collected over each 30 minute
period (U2-U6), an i.v. bolus of chlorothiazide (500 mg) was
administered while continuing the furosemide infusion. Urine
was collected for the next 30 minutes (U7) and blood taken at
the midpoint. BP and heart rate (HR) were recorded every 30
minutes with an automatic BP recorder (Bard Biomedical,
Lombard, Illinois, USA).
Laboratory analyses
Details of the chemical methods used for analysis have been
published [2, 18]. Na and K concentrations in plasma and urine
were measured by flame photometer (IL 443, Fisher Scientific,
Orlando, Florida, USA); chloride (CI) potentiometrically
(920M, Corning Inc., Corning, New York, USA); PAH colon-
metrically. BUN and Sr concentrations were measured by
autoanalyzer (Parallel Analyses; American Monitor Corp., In-
dianapolis, Indiana, USA). Plasma bicarbonate concentration
(PHC0,) was determined from analysis of aterialized venous
blood (ABL 300 Radiometer, Copenhagen, Denmark). PRA
was measured by a specific radioimmunoassay for angiotensin I
(Al) (Genetech, Travenol, Cambridge, Massachusetts, USA).
Urinary furosemide concentration was determined after extrac-
tion of 1 ml samples into 10 ml ether and drying under nitrogen.
An internal standard of bumetanide (10 tg . mI') was added to
urines prior to extraction; recovery averaged 80 to 85%. The
samples were reconstituted in methanol and injected into an
HPLC analyzer (LDC/Milton Roy, Palm Beach, Florida, USA).
Reverse phase chromatography with a C,8 bondapak column
(Waters, Guilford, Massachusetts, USA) was carried out using
a mobile phase gradient from 40 to 60% methanol: water and
3.6% glacial acetic acid. Retention times of 4.7 and 9.6 minutes
were seen for furosemide and bumetanide, respectively. Furo-
semide was detected on a fluorescence monitor (RF530, Shi-
madzu, Kyoto, Japan), with excitation and emission wave-
lengths of 405 and 350 nm, respectively [2].
Data analysis
Mean arterial BP (MABP) was calculated as diastolic BP plus
1/3 the pulse pressure; the diastolic BP was taken as the fifth
Korotkoff sound. Renal blood flow (RBF) was calculated from
Hct and PAH clearance without measurement of renal PAH
extraction; filtration fraction (FF) from GFR divided by renal
plasma flow (RPF) which was equated with PAH clearance;
fractional electrolyte excretion (FENa, etc.) from the
urine:plasma ratios of each divided by the ratios for DTPA; PV
from the immediate volume of distribution of Evans Blue, and
the change in PV following i.v. furosemide from the formula:
/PVb x Hctb\ /100 — Hctb
PVb —
100 — Hctb) HCtf
where b and fare basal and furosemide values, respectively.
Data were analyzed by two-way analysis of variance (factors:
treatment group and subject); when treatment groups were
significantly different (P < 0.05), comparisons were made by
paired i-test with the placebo (P) group (P < 0.05). In addition,
some data was analyzed by comparing the F group with F + S
to assess the role of aldosterone in the response to long-term
furosemide and F with C to assess any differences in response
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Table 1. Blood pressure, body weight, 24 hour urine electrolyte excretion and body fluid volumes after 1 month of placebo or diuretic
treatments
P C F F+S
MABPmmHg ll6±5 l07±3a l08±4 lO4±5'
Body wt kg 94.4 7.0 92.1 6.8 93.5 7.0 96.6 9.7
UNaV mmol 24 hr'
U1V mmol . 24 hr' 122.8 20,0129.5 20.9 95.3 21.196.1 + 122.5 20.4129.3 22.6 138.2 25.2157.0 26.3
UKV mmol 24 hr' 60.1 9.8 63.3 9,9 60.4 10.1 70.8 11.8
ECV liter 18.7 1.5 l8,3 1.7 18.1 1.8 16.8 1.4
PV liter 3.5 0.2 3.7 0.4 3.6 0.3 3.4 0.4
Results are mean saM;N = 8, except F + S, where N = 5. The 24-hr excretion data refers to averaged data obtained over the 48 hr period
prior to the experimental day. Abbreviations are: P, placebo; C, chiorothiazide; F, furosemide; F + S, furosernide plus spironolactone; MABP,
mean arterial blood pressure; Body wt, body weight; UNaV etc., renal electrolyte excretion; PV, plasma volume.
a P < 0.01 and b 0.05, respectively, compared to placebo by paired 1-test and following a 2-way analysis of variance (factors: treatment group
and subject; P < 0.05)
to the two diuretic pretreatments. Values for PRA were log-
transformed for statistical analysis. All results are expressed as
means SEM.
Results
All subjects completed each study protocol and did not
experience any adverse effects. Mean daily renal electrolyte
excretion, body weight, basal MABP and PV are given in Table
I. Compared with P, treatment with C and F + S reduced
MABP significantly. There were no significant differences in 24
hour Na and K excretions although 24 hour Cl excretion was
reduced significantly during chlorothiazide treatment.
The patterns of six hour UNaV during P and F therapy are
shown in Figure 1. F therapy, taken at 08.00 and 20.00 hours,
increased UNaV well above levels seen at comparable times of
the day during P; this was followed by periods of decreased
excretion below P levels. Since F-induced increases in UNaV
were consistently followed by decreases during the post-di-
uretic phase, this resulted in comparable 24 hour rates of net
UNaV (Table I).
Plasma concentrations of electrolytes, including bicarbonate,
BUN and Se,. following one month of each treatment, are given
in Table 2. Compared with P, both C and F therapy reduced K
and P1.
Table 3 gives the mean values of UV and electrolyte excre-
tion, GFR, RBF (calculated from Hct and clearance of PAH
without measurement of extraction) and FF before short-term
furosemide infusion. C and F treatments both reduced basal
UNaV and UV. The U1V was in fact lower during F than C
treatment (P < 0.01). Basal UNaV after F + S was not
significantly different from P, but U1V and renal potassium
excretion (UKV) were reduced. Moreover, UNaV was higher (P
< 0.05) and UKV lower (P < 0.02) comparing F + S with F
alone.
During short-term furosemide infusion, PV fell by 9% and HR
increased by 9 beats . min; there were no significant differ-
ences between treatments (data not shown). Acute furosemide-
stimulated levels of PRA in groups P, C and F were 2.37 1.07,
14.45 4.46 and 5.59 2.73 ng A! . ml' . hr, respectively.
PRA rose acutely during furosemide infusion in each group (P
<0.05 compared with P), but the rise was most marked after
one month of C treatment.
Short-term furosemide infusion was associated with small
increments in GFR which were similar in each group (Table 4).
The calculated RBF increased during furosemide infusion only
during F and C therapy. There were no significant changes in
FF. There were sharp increases in UV, UNaV, U1V and UKV.
However, as shown in Table 4, the absolute rises in UNaV,
U1V and UKV during the furosemide infusion were attenuated
after one month of diuretic treatment. In the smaller numbers of
subjects studied, the effect of F + S treatment on UNaV, U1V
and UKV were not significantly different from F alone.
The individual changes in FENa produced by short-term
furosemide infusions are shown in Figure 2A. After P, the
infusions increased FENa by 10.5 0.7%; after one month of F
or C therapy, the increases were significantly reduced to 8.9
0.7 and 8.5 1.0%, respectively (P < 0.05). The addition of
spironolactone (F + S) did not restore the impaired response
which was similar to F alone.
The effects of giving i.v. chlorothiazide during the furosemide
test infusion are shown in Figure 2B. After P, there was a
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Fig. 1. Mean values for the pattern of renal sodium excretion (UN, V)
during twice daily oral administration (08.00 and 20.00 hr) of placebo
(P) compared with furosemide (F).
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Table 2. Plasma electrolytes after I month of placebo or diuretic 14 hours after the last drug dose
P C F F+S
'DNa mmol. liter'
P1( mmol. !iter'
139.4 0.8
4,21 0.12
138.6 1.0
3.49 O.l2
138.8 0.6
3.81 0.il'
137.84 0.5
4.05 0.14
Pc1 mmol liter'
HCO3 mmol liter'BUN mg . d1'
103.5 0.7
25.6 0.6
13.9 1.1
99.4 l7b
27.1 0.7
17.3 0.8
101.0 05b
26.7 0.7
17.6 1.9
101.5 0.7
25.4 0.6
17.4 1.9
Scr mg d1' 1.16 0.06 1.20 0.07 1.21 0.08 1.28 0.04
Abbreviations are: P, placebo; C, chlorothiazide; F, furosemide; F + S, furosemide plus spironolactone; Na, etc., plasma electrolyte
concentration; BUN, blood urea nitrogen; Sr, serum creatinine concentration. Results are mean SEM; N = 9, except F ÷ S, where N = 6.
a and b signify P < 0.01 and 0.05, respectively, compared to placebo by paired f-test following a 2-way analysis of variance (factors: treatment
group and subject; P < 0.05).
Table 3. Basal urine flow rate, renal electrolyte excretion, glomerular filtration rate, and renal blood flow after I month of placebo or diuretic
treatments and before acute furosemide infusion; 14 hours after the last drug dose
P C F F+S
V ml min'
UNaVlLflol.min'
Uc,V.unolmin
UKV,.unol.min'GFR ml min'
ERBFmI.min'
FF %
2.88 0.51
167
156±24
68±11
94.8 10.2
794± 127
22.0 1.7
2.04 0.35
78± l7
71±24"
51±37
94.8 8.2
771 104
23.5 1.8
2.03 0.43
63± l1
25±5a
50±8
91.7 6.1
757± 112
25.3 2.8
1.68 0.23
116±14
4114b377b
93.8 9.9
727± 123
23.8 1.9
Results are mean SEM; N = 9, except F + S, where N = 6. Abbreviations are: UV, urine flow rate; UNaV etc., urine electrolyte excretion;
GFR, glonierular filtration rate; RBF, renal blood flow; FF, filtration fraction; P, placebo; C, chlorothiazide; F, furosemide; F + S. furosemide plus
spironolactone.
a and b
signify P < 0.01 and 0.05, respectively, compared with placebo by paired 1-test following a 2-way analysis of variance (factors: treatment
group and subject; P < 0.05).
Table 4. Changes in urine flow rate, renal electrolyte excretion,
furosemide infusion, after I
glomerular filtration rate, renal blood flow
month of placebo or diuretic treatments
and filtration fraction during acute
P C F F+S
UV ml. min'
UNaV pinol . min'
U1V p.mol. min
UKV .unol. min'
GFR ml. min'
RBFmI. min'
FF%
+12,53 0.89
+ 1571 117
+ 1823 125
+162 20
+14.1 8.2
+23 68
+2.8 1.1
+11.84 1.22 +11.16
1347 152l + 1303
1552 163 + 1424
+104 l6 +115
+18.7 6.8 +15.9
+151 66l +201
—0.5 0.8 —3.8
1.09l3l
l44
l5l
7.3
87
3.0
+11.49 1.30
+1250 1Mb
+1379 158b
+91 10
+6.6 4.1
—4 53
+1.1 1.5
Results are mean SEM; N = 9, except F + S, where N = 6. Abbreviations are: P, placebo; C, chlorothiazide; F, furosemide; F + S. furosemide
plus spironolactone; UV, urine flow rate; UNaV, etc., urine electrolyte excretion; GFR, glomerular filtration rate; RBF, renal blood flow; FF,
filtration fraction.
a and b signify P < 0.01 and 0.05, respectively, compared with placebo by paired 1-test following a 2-way analysis of variance (factors: treatment
group and subject; P < 0.05).
further increase in FENa of 7.5 1.2%. After one month of C
therapy, the increase was not significantly different from P, but
after F treatment, the rise in FENa following i.v. chlorothiazide
was significantly greater at 10.1 1.4%. Spironolactone (F + S)
did not affect the augmented response which was similar to F
alone.
Finally, as shown in Figure 3A, renal furosemide excretion
was reduced after C or F compared with P. The effect of this
pharmacokinetic adaptation was to decrease sharply the UNaV
per unit of furosemide excretion after treatment with C or F
(Fig. 3B).
Discussion
At the start of diuretic therapy, the initial NaCI loss is
followed by a new steady state when daily output matches
intake. Our results in hypertensive subjects studied after one
month of diuretic therapy demonstrate that this is achieved by
a combination of renal NaCI retention in the post-diuretic
period and by a resistance to the natriuretic response to
furosemide.
Previous studies [2] of the early phase of adaption to diuretic
therapy in normal subjects have shown that resistance to the
natriuretic response to furosemide develops after three days of
furosemide administration given during a low NaCI diet, while
a reduced UNaV in the post-diuretic phase is apparent at more
liberal NaCl intakes. The present study demonstrates that
post-diuretic Na retention persists during prolonged furosemide
treatment for hypertension and is quantitatively more important
for maintaining NaCl and water balance (Fig. 1). This study was
not designed to specifically investigate the mechanism of post-
E>
Fig. 2A. Paired individual changes in
fractional sodium excretion (FEN,) during
acute i.v. furosemide infusion, comparing the
response after each diuretic treatment (C, F,
F + S) with the response after placebo (P).
** indicates P < 0.01 compared with P, after
ANOVA; for F + S, P = 0.068. B. Paired
individual augmented changes in fractional
sodium excretion (FENa) during acute
furosemide infusion following the addition of
i.v. chlorothiazide, comparing the response
after each diuretic treatment (C, F, F + S)
with the response after placebo (P). ** and *
indicate P < 0.05 and < 0.01, respectively,
compared with P, after ANOVA; for F + S. P
= 0.19.
diuretic Na retention. Nevertheless, a reduced UNflV following
the diuresis was also evident as a reduced basal rate of UNaV Ofl
the experimental days 12 to 14 hours after the last doses of C or
F therapy (Table 3). The effect was more prominent after F than
C therapy, perhaps relating to the longer duration of action of
C. At this time, the reduced UNUV was not associated with
persistent changes in PV, GFR, or RBF although MABP was
reduced. This confirms previous studies of hydrochlorothiazide
therapy for hypertension which have shown that initial de-
creases in PV, GFR and RBF return to pre-treatment values
within 6 to 12 weeks of continuous therapy [9, 10]. PRA was
elevated during C and F therapy. Moreover, the basal UNaV
was higher and UKY lower during F + S compared to F alone
(Table 3). This suggests that the renin-angiotensin-aldosterone
axis was indeed activated by diuretic therapy, and the response
to the aldosterone antagonist suggests that aldosterone may
have conditioned the kidney to enhanced Na reabsorption and
K secretion during the post-diuretic phase. However, during
the early phase of adaption to furosemide administration at a
higher level of dietary salt intake, we observed that post-
diuretic Na and K retention were not prevented by frequent
doses of captopril sufficient to prevent any furosemide-induced
changes in plasma angiotensin II or aldosterone concentrations
[4, 5]. Other factors must contribute to post-diuretic changes in
electrolyte excretion which were not identified in this investi-
gation.
A reduced response to the test furosemide infusion after one
month of diuretic therapy was seen despite a well-maintained
GFR; therefore, it must be due to a blunted effect of furosemide
on tubular Na reabsorption. Can this resistance to furosemide
be ascribed to a reduced response in the loop of Henle? This
seems unlikely since prolonged chiorothiazide administration
produced a similar effect and this diuretic does not act primarily
on the loop [19]. Moreover, after prolonged furosemide infusion
in the rat, there are no major changes in the Na-K-ATPase
activity [14, 151 of the loop of Henle, nor are there changes in
the fluid, Na or K transport in the ioop during microperfusion
[16].
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Fig. 3A. Paired individual values for renal
furosemide excretion during furosemide
infusion after C or F therapy, compared to P.
< 0.05 compared with P, after ANOVA. B.
Paired individual values for urinary sodium to
furosemide concentration during furosemide
infusion. *p < 0.05 compared with F, after
ANOVA.
Can the reduced response to the test furosemide infusion
seen after one month of diuretic therapy be ascribed to altered
furosemide kinetics? Furosemide's action depends on proximal
tubular secretion and delivery to the loop of Henle [20].
However, renal furosemide excretion was actually increased
during furosemide infusion following prolonged diuretic therapy
(Fig. 3A). The reason for this is not clear. We considered that
increased furosemide excretion might be related to the furo-
semide-induced increase in RBF (calculated from PAH clear-
ance without knowledge of its renal extraction) which occurred
during prolonged F and C therapy. However, there was no
correlation between furosemide excretion and RBF in these
studies (r = 0.23; NS). Nevertheless, the result of this diuretic-
induced increase in furosemide excretion was a sharp decrease
in UNaV perunit of furosemide delivered to the urine (Fig. 3B).
Thus, the overall reduction in renal responsiveness to furo-
semide following F or C therapy occurred despite the pharma-
cokinetic adaptation which actually increased delivery of furo-
semide to the urine.
Can the decreased response to furosemide infusion during
prolonged diuretic therapy be ascribed to decreased delivery of
NaCl to the loop of Henle? Short-term diuretic administration
can reduce the GFR and increase proximal fluid reabsorption.
However, these changes have been related to extracellular fluid
volume (ECV) depletion [21, 22]. In the present study, mea-
surements of PV were unchanged, although body weight was
reduced slightly following one month of diuretic therapy. Ear-
ley and Martino [22] used a combination of loop diuretic and
thiazide to block the major distal NaCI reabsorptive sites in
man; the residual NaCI reabsorption was ascribed to the
proximal tubule. In the present study, the FE1 during com-
bined furosemide infusion and chiorothiazide injection aver-
aged 26 2% during P therapy. When assessed by ANOVA,
this was not different (P> 0.1) from the corresponding values of
.—.
I I
15
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5
0—
B
30
20
z 10
P C P F F F+S
f I
P C P F
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22 2% during C, 26 2% during F and 29 1% during
F + S. Likewise, ANOVA indicated no significant effect of
prior treatment on FENa measured at this time. This provides
indirect evidence that proximal NaC1 reabsorption was main-
tained following furosemide therapy. After one month of di-
uretic therapy, there was a small, although not significant, trend
towards a reduction in FF which might be expected to reduce,
rather than to increase, proximal tubular fluid reabsorption [23].
Despite these arguments, proximal reabsorption was not as-
sessed directly in these studies. Therefore, we cannot exclude
the possibility that unrecognized changes in proximal reabsorp-
tion contributed to the decreased natriuretic response to furo-
semide infusion during diuretic therapy.
Can the decreased response to furosemide infusion during
prolonged diuretic therapy be related to hyperaldosteronism?
Both furosemide and chiorothiazide did indeed increase PRA.
However, increased aldosterone levels seem unlikely to have
been the major cause of the decreased response to furosemide
since the aldosterone antagonist, spironolactone, did not re-
store furosemide-stimulated UNaV to levels seen during pla-
cebo administration (Table 4 and Fig. 2A). The dose and timing
of spironolactone administration were chosen to correspond to
its maximal effects in man [20, 24]. Moreover, F + S increased
basal UNaV and decreased basal UKV, compared to F alone.
This suggests that spironolactone was effective in these proto-
cols in blunting the renal action of aldosterone. However, the
major sites of aldosterone action beyond the distal convoluted
tubule have a limited capacity to reabsorp Na which could be
overwhelmed by the considerable natriuresis evoked by furo-
semide infusion. Therefore, it seems unlikely that enhanced
reabsorption via aldosterone-sensitive sites was the major
cause of the reduced natriuretic response to furosemide during
prolonged diuretic therapy.
Can the reduced response to furosemide infusion during
diuretic therapy be ascribed to enhanced reabsorption in the
distal tubule? Hypertrophy of the distal convoluted tubule has
been reported after six to eight days of continuous furosemide
infusion in rats [1 1—131 and attributed to increased NaC1 deliv-
ery and transport. An enhanced Na-K-ATPase activity of this
segment was reported following prolonged infusion of furo-
semide into rats at a high dose [14], whereas furosemide
infusion at a lower dose stimulated the enzyme only in the
collecting ducts [15]. Microperfusion of the distal tubule has
shown increased capacity to reabsorb Na F 121 independent of
corticosteroids [16]. The distal convoluted tubule of the rat has
a luminal thiazide-sensitive, electroneutral NaCI co-transport-
er, but no significant K-secretory pathway [191. An enhanced
capacity of the distal convoluted tubule to reabsorb Na follow-
ing adaptation to furosemide therapy could account for our
finding of an enhanced response to chlorothiazide injection
during furosemide infusion in the hypertensive subjects receiv-
ing furosemide therapy (Table 4). Rats given furosemide or
hydrochlorothiazide for three to eight days also have enhanced
Na-K-ATPase activity along the cortical collecting ducts [14,
15, 25]. This effect is apparently independent of aldosterone [15]
and may be secondary to increased delivery of filtrate due to
blockade of reabsorption upstream. Moreover, furosemide ad-
ministration causes hypertrophy of cells of the collecting tubule
and collecting ducts [12, 13], notably the principal cells [13].
Therefore, adaption at the distal convoluted tubule and beyond
could have contributed to reduced Na loss during prolonged
diuretic therapy.
Our studies also demonstrated a decreased natriuretic re-
sponse to furosemide during chlorothiazide therapy. As with
prolonged furosemide therapy, this cannot be related to a
decreased PV, GFR or RBF. However, unlike the effects of
furosemide, chlorothiazide therapy did not change the response
to chlorothiazide injection. Therefore, it seems unlikely that the
distal convoluted tubule was the major site of enhanced Na
reabsorption. Indeed, prolonged thiazide administration to rats
increases the Na-K-ATPase activity of the collecting ducts [25].
However, the mechanism of the adaptive changes in reabsorp-
tion during chlorothiazide therapy were not studied further.
In summary, we found that prevention of progressive NaCI
losses during prolonged furosemide therapy was due to a
combination of reduced NaCI excretion during the post-diuretic
phase and reduced natriuretic response to furosemide. This
reduced response occurred despite increased tubular delivery
of diuretic, and was accompanied by evidence of an increase in
NaCI reabsorption at a thiazide-sensitive nephron segment such
as the distal convoluted tubule. Finally, these observations may
provide a rational basis for the use of thiazide and loop diuretic
combinations in the treatment of patients with severe edema
resistant to large doses of loop diuretics alone [26, 27].
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